Xenikos Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Xenikos General Information

Description

Developer of an immune-reset therapy designed to treat severe immune-related conditions. The company's therapy aims to restore immune system function and has been studied in patients with steroid-refractory acute graft-versus-host disease, with potential applications in organ rejection and autoimmune diseases, enabling patients and healthcare providers to access treatment options when standard steroid therapy fails.

Contact Information

Website
www.xenikos.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wilhelminasingel 14
  • 6524 AL Nijmegen
  • Netherlands
+31 024
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Wilhelminasingel 14
  • 6524 AL Nijmegen
  • Netherlands
+31 024

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xenikos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 04-Apr-2026 Completed Clinical Trials - Phase 3
6. Grant 05-Oct-2022 Completed Clinical Trials - Phase 3
5. Later Stage VC 02-Sep-2021 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 15-May-2018 Completed Pre-Clinical Trials
3. Grant 03-Jan-2017 Completed Pre-Clinical Trials
2. Later Stage VC 14-Oct-2016 $2.24M $9.1M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 19-Jun-2012 $6.9M $6.9M Completed Pre-Clinical Trials
To view Xenikos’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Xenikos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune-reset therapy designed to treat severe immune-related conditions. The company's therapy aims to r
Drug Discovery
Nijmegen, Netherlands
17 As of 2022

South San Francisco, CA
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xenikos Competitors (52)

One of Xenikos’s 52 competitors is Neurona Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
AnTolRx Formerly VC-backed Cambridge, MA
Baliopharm Venture Capital-Backed Basel, Switzerland
NeuroNascent Venture Capital-Backed Clarksville, MD
Enterome Venture Capital-Backed Paris, France
You’re viewing 5 of 52 competitors. Get the full list »

Xenikos Patents

Xenikos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201717966-D0 Immunotoxins, formulations thereof and their use in medicine Inactive 31-Oct-2017
US-11447548-B2 Immunotoxins, formulations thereof and their use in medicine Active 31-Oct-2017
US-20200407443-A1 Immunotoxins, formulations thereof and their use in medicine Active 31-Oct-2017
WO-2019086534-A1 Immunotoxins, formulations thereof and their use in medicine Inactive 31-Oct-2017
GB-201617487-D0 Reducing viral infection and/or viral reactivation during immunotherapy Inactive 14-Oct-2016
To view Xenikos’s complete patent history, request access »

Xenikos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xenikos Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator Minority
Veloxis Pharmaceuticals Corporation Minority
Medicxi Ventures (UK) Venture Capital Minority
RA Capital Management Asset Manager Minority
Stitching Participatie Xenikos Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Xenikos FAQs

  • When was Xenikos founded?

    Xenikos was founded in 2009.

  • Where is Xenikos headquartered?

    Xenikos is headquartered in Nijmegen, Netherlands.

  • What is the size of Xenikos?

    Xenikos has 17 total employees.

  • What industry is Xenikos in?

    Xenikos’s primary industry is Drug Discovery.

  • Is Xenikos a private or public company?

    Xenikos is a Private company.

  • What is Xenikos’s current revenue?

    The current revenue for Xenikos is .

  • How much funding has Xenikos raised over time?

    Xenikos has raised $86.2M.

  • Who are Xenikos’s investors?

    European Innovation Council, Veloxis Pharmaceuticals, Medicxi Ventures (UK), RA Capital Management, and Stitching Participatie Xenikos are 5 of 7 investors who have invested in Xenikos.

  • Who are Xenikos’s competitors?

    Neurona Therapeutics, AnTolRx, Baliopharm, NeuroNascent, and Enterome are some of the 52 competitors of Xenikos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process